2022

STOCKHOLM, November 3[rd], 2022 – In accordance with the resolution of the Annual General Meeting on May 16[th], 2022, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 16[th], 2022.

STOCKHOLM, August 4[th], 2022, Moberg Pharma AB (OMX: MOB) has signed a distribution agreement with Padagis Israel Agencies Ltd. for MOB-015 in Israel and the Palestinian territories. Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.

STOCKHOLM, 8 June 2022. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) has today resolved on a directed new issue of 536,952 ordinary shares to the guarantors in the rights issue of ordinary shares resolved upon by the Board of Directors on 8 April 2022 and approved by the Extraordinary General Meeting on 3 May 2022 (the “Rights Issue”) who have chosen to receive their guarantee commission in the form of newly issued ordinary shares in Moberg Pharma (the "Remuneration Issue"). The subscription price in the Remuneration Issue corresponds to the subscription price in the Rights Issue, SEK 2.30 per ordinary share, and payment is made by set-off of claims.

STOCKHOLM, 31 May 2022. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) today announces the outcome of the fully guaranteed rights issue of ordinary shares with preferential rights for Moberg Pharma’s shareholders (the “Rights Issue”) which was resolved upon by the Board of Directors on 8 April 2022 and approved by an extraordinary general meeting on 3 May 2022. In total, 24,305,220 ordinary shares were subscribed for with support of subscription rights, corresponding to approximately 46.3 percent of the Rights Issue. 775,636 ordinary shares, corresponding to approximately 1.5 percent of the Rights Issue, have been allotted to persons who have subscribed for ordinary shares without support of subscription rights. Therefore, the issue guarantors are allotted approximately 52.2 percent of the Rights Issue. Moberg Pharma will receive approximately SEK 120.8 million before deduction for transaction costs.

Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) announces that the prospectus relating to the Company’s rights issue of ordinary shares (the “Rights Issue”) has been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company’s website www.mobergpharma.se/investerare/prospekt and will also be available at the Swedish Financial Supervisory Authority’s website www.fi.se.

Moberg Pharma AB (OMX: MOB) today announced that patient enrollment has started in the North American Phase 3 study for MOB-015 (nail fungus treatment).

STOCKHOLM, April 29[th], 2022, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 46,681,123 due to the completion of the previously announced exercise of warrants of series 2020:1.

Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426, (the “Company”) are hereby convened to the Annual General Meeting on 16 May 2022.

STOCKHOLM, 8 April 2022. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or “the Company”) has today resolved to carry out a fully guaranteed issue of new ordinary shares with preferential rights for existing shareholders (the “Rights Issue”) of approximately SEK 121 million before transaction costs. The Rights Issue is conditional upon approval at an extraordinary general meeting (the “Extraordinary General Meeting”). The net proceeds will be used for registration activities and clinical work for MOB-015.

Moberg Pharma AB (publ) have submitted its marketing authorization application for MOB-015 (nail fungus treatment). The company has submitted the application in Europe through the decentralized procedure, and market approval is expected in 2023.

Moberg Pharma AB (publ) has submitted regulatory filing for the next clinical Phase 3 study for MOB-015 (nail fungus treatment) to the U.S. Food and Drug Administration (FDA).

STOCKHOLM, March 14[th], 2022. Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") hereby announces that the subscription price for warrants of series 2020:1 is SEK 6.47. The exercise period begins on 16 March 2022 and runs until 29 March 2022. The last day for trading in warrants of series 2020:1 on Nasdaq Stockholm is 25 March 2022.